Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) EPS (Weighted Average and Diluted) (2020 - 2025)

Exagen (XGN) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.21 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 5.0% year-over-year to -$0.21, compared with a TTM value of -$0.93 through Dec 2025, down 12.05%, and an annual FY2025 reading of -$0.93, down 12.05% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.21 for Q4 2025 at Exagen, up from -$0.31 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.16 in Q2 2024 and bottomed at -$0.86 in Q2 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.38, with a median of -$0.31 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 126.32% in 2022, then soared 67.44% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.4 in 2021, then tumbled by 110.0% to -$0.84 in 2022, then surged by 63.1% to -$0.31 in 2023, then soared by 35.48% to -$0.2 in 2024, then fell by 5.0% to -$0.21 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for XGN at -$0.21 in Q4 2025, -$0.31 in Q3 2025, and -$0.21 in Q2 2025.